Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF02749729 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Are handheld dynamometers a valid alternative to isokinetic devices for assessing the shoulder rotators in neurogenic thoracic outlet syndrome?
Ann Phys Rehabil Med
January 2025
Service de Médecine Physique et Réadaptation Locomotrice et Respiratoire, CHU Nantes, Nantes Université, 85 rue Saint Jacques, 44093 Nantes, Cedex 1, France; Service de Médecine du Sport, CHU Nantes, Nantes Université, 85 rue Saint Jacques, 44093 Nantes, Cedex 1, France; Inserm, UMR 1229, RMeS, Regenerative Medicine and Skeleton, ONIRIS, Nantes Université, 1 place Alexis Ricordeau, 44000 Nantes Cedex 1, France; Institut Européen de la Main, Hôpital Kirchberg, 9, rue Edward Steichen, L-254 Luxembourg, Luxembourg; Medical Training Center, Hôpital Kirchberg, L2540 Luxembourg, Luxembourg; Institut Régional de Médecine du Sport (IRMS), 85 rue Saint Jacques, 44093 Nantes, Cedex 1, France. Electronic address:
Pharmacokinetic and Metabolomic Studies with BBT-059 in Nonhuman Primates Exposed to Total-Body Gamma Radiation.
Radiat Res
December 2024
Division of Radioprotectants, Department of Pharmacology and Molecular Therapeutics, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland.
BBT-059 is a long-acting PEGylated interleukin-11 analog that has been shown to have hematopoiesis-promoting and anti-apoptotic attributes, and is being studied as a radiation countermeasure for the hematopoietic acute radiation syndrome (H-ARS). This potential countermeasure has been demonstrated to enhance survival in irradiated mice. To investigate the toxicity and safety profile of this agent, 14 nonhuman primates (NHPs, rhesus macaques) were administered two different doses of BBT-059 subcutaneously 24 h after 4 Gy total-body irradiation and were monitored for the next 60 days postirradiation.
View Article and Find Full Text PDFHospital-level volume in extracorporeal membrane oxygenation cases and death or disability at 6 months.
Crit Care Resusc
December 2024
Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia.
Objective: Extracorporeal membrane oxygenation (ECMO) is a high-risk procedure with significant morbidity and mortality and there is an uncertain volume-outcome relationship, especially regarding long-term functional outcomes. The aim of this study was to examine the association between ECMO centre volume and long-term death and disability outcomes.
Design Setting And Participants: This is a registry-embedded observational cohort study.
Impact of the COVID-19 Pandemic on the Use of Quaternary Ammonium Compound Disinfectants in Healthcare Facilities Within Selected States in the United States of America.
Cureus
December 2024
Anatomy/Embryology, Edward Via College of Osteopathic Medicine - Virginia, Blacksburg, USA.
Introduction Quaternary ammonium compounds (QACs) are the active ingredient in the majority of disinfectants approved for use against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19). Although widely used, they have been linked to infertility and birth defects in animals, and have been shown to increase proinflammatory cytokines, decrease mitochondrial function, and disrupt sterol biosynthetic pathways in a dose-dependent manner in humans. This study examined if there was an increased use of QAC-based disinfectants among healthcare settings in response to the COVID-19 pandemic and aims to bring to light the negative health outcomes that this rise in QAC exposure may pose.
View Article and Find Full Text PDFEfficacy of Amitriptyline in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis.
J Neurogastroenterol Motil
January 2025
Department of Psychiatry and Psychology, Cleveland Clinic, Cleveland, OH, USA.
Background/aims: Amitriptyline is prescribed off-label for irritable bowel syndrome (IBS). We conducted a meta-analysis to assess its efficacy.
Methods: A systematic literature review was conducted until November 10, 2023, using MEDLINE, Embase, Cochrane Library, and Web of Science to study the efficacy of amitriptyline in patients with IBS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!